884
Views
12
CrossRef citations to date
0
Altmetric
Preliminary Reports

Stability of Tranexamic Acid after 12-Week Storage at Temperatures from –20°C to 50°C

, Jr., MT, , BS, , PhD, , PhD, , MD, PhD & , PhD
Pages 394-400 | Received 03 Jan 2013, Accepted 14 Mar 2013, Published online: 04 Jun 2013

References

  • Blackbourne LH, Czarnik J, Mabry R, Decreasing killed in action and died of wounds rates in combat wounded. J Trauma. 2010;69(suppl 1):S1–4.
  • Kelly JF, Ritenour AE, McLaughlin DF, Injury severity and causes of death from Operation Iraqi Freedom and Operation Enduring Freedom: 2003–2004 versus 2006. J Trauma. 2008;64(suppl 1):S21–6; discussion S26–7.
  • Evans JA, van Wessem KJ, McDougall D, Lee KA, Lyons T, Balogh ZJ. Epidemiology of traumatic deaths: comprehensive population-based assessment. World J Surg. 2010;34:158–63.
  • Ngaage DL, Bland JM. Lessons from aprotinin: is the routine use and inconsistent dosing of tranexamic acid prudent? Meta-analysis of randomised and large matched observational studies. Eur J Cardiothorac Surg. 2010;37:1375–83.
  • Zhang H, Chen J, Chen F, Que W. The effect of tranexamic acid on blood loss and use of blood products in total knee arthroplasty: a meta-analysis. Knee Surg Sports Traumatol Arthrosc. 2012;20:1742–52.
  • Shakur H, Roberts I, Bautista R, Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet. 2010;376:23–32.
  • Morrison JJ, Dubose JJ, Rasmussen TE, Midwinter MJ. Military Application of Tranexamic acid in Trauma Emergency Resuscitation (MATTERS) Study. Arch Surg. 2012;147:113–9.
  • Joint Theater Trauma Systems. Damage control resuscitation at level IIb/ III treatment facilities. Clinical Practice Guideline. 2013. Available at: http://www.usaisr.amedd.army.mil/ assets/cpgs/Damage%20Control%20Resuscitation%20-%201%20Feb%202013.pdf. (accessed 2 May 2013).
  • Roberts I, Shakur H, Afolabi A, The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. Lancet. 2011;377:1096–1101, 1101 e1091–1092.
  • Brown LH, Krumperman K, Fullagar CJ. Out-of-hospital medication storage temperatures: a review of the literature and directions for the future. Prehosp Emerg Care. 2004;8: 200–6.
  • Food and Drug Administration. Guidance for industry. Q1a(r2) stability testing of new drug substances and products. 2003.
  • Department of Defense. Shelf-Life Management Manual. Washington, DC: Department of Defense, 2005.
  • Rijken DC, Sakharov DV. Molecular transport during fibrin clot lysis. Fibrinol Proteol. 2000;14:98–113.
  • Rijken DC, Sakharov DV. Basic principles in thrombolysis: regulatory role of plasminogen. Thromb Res. 2001;103(suppl 1):S41–9.
  • Maksimenko AV, Tischenko EG. Macromolecular ensembles of internal and external fibrinolysis: the resources for enhancement of thrombolysis efficacy. Curr Med Chem. 2006;13:1617–25.
  • Godier A, Roberts I, Hunt BJ. Tranexamic acid: less bleeding and less thrombosis? Crit Care. 2012;16:135.
  • Roberts I, Shakur H, Ker K, Coats T. Antifibrinolytic drugs for acute traumatic injury. Cochrane Database Syst Rev. 2011:CD004896.
  • Frith D, Brohi K. The pathophysiology of trauma-induced coagulopathy. Curr Opin Crit Care. 2012;18:631–6.
  • Niles SE, McLaughlin DF, Perkins JG, Increased mortality associated with the early coagulopathy of trauma in combat casualties. J Trauma. 2008;64:1459–63; discussion 1463–65.
  • Cotton BA, Harvin JA, Kostousouv V, Hyperfibrinolysis at admission is an uncommon but highly lethal event associated with shock and prehospital fluid administration. J Trauma Acute Care Surg. 2012;73:365–70; discussion 370.
  • Kutcher ME, Cripps MW, McCreery RC, Criteria for empiric treatment of hyperfibrinolysis after trauma. J Trauma Acute Care Surg. 2012;73:87–93.
  • Schochl H, Voelckel W, Maegele M, Solomon C. Trauma-associated hyperfibrinolysis. Hamostaseologie. 2012;32:22–7.
  • Theusinger OM, Wanner GA, Emmert MY, Hyperfibrinolysis diagnosed by rotational thromboelastometry (ROTEM) is associated with higher mortality in patients with severe trauma. Anesth Analg. 2011;113:1003–12.
  • Ives C, Inaba K, Branco BC, Hyperfibrinolysis elicited via thromboelastography predicts mortality in trauma. J Am Coll Surg. 2012;215:496–502.
  • Hoffmann JJ, Vijgen M. Prevention of in vitro fibrinogenolysis during laboratory monitoring of thrombolytic therapy with streptokinase or APSAC. Blood Coagul Fibrinolysis. 1991;2:279–84.
  • Pfizer Canada Inc. Product monograph cyklokapron. Quebec City, Canada. 2010. Available at: http://www.pfizer.ca/en/ our_products/products/monograph/195. (date accessed 6 Feb 2013).
  • Pfizer Inc. Cyklokapron® tranexamic acid injection. New York, NY. 2011. Available at: http://www.accessdata.fda.gov/ drugsatfda_docs/label/2011/019281s030lbl.pdf. (date accessed 6 Feb 2013).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.